Tigress Financial Maintains Buy on Medline, Raises Price Target to $62

Benzinga Newsdesk www.benzinga.com Positive 75.6%

Neg 0% Neu 0% Pos 75.6%

Tigress Financial analyst Ivan Feinseth maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $60 to $62.